Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 27Recruiting 16Terminated 12Unknown 6Active not recruiting 4Not yet recruiting 3Withdrawn 1Suspended 1No longer available 1Enrolling by invitation 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Neoplasms 19Prostatic Neoplasms 9Breast Neoplasms 9Melanoma 8Colorectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Pancreatic Neoplasms 6Neoplasm Metastasis 6Ovarian Neoplasms 5Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Solid Tumors 4Myelodysplastic Syndromes 4Leukemia, Myeloid, Acute 4Glioblastoma 4Carcinoma, Renal Cell 4Stomach Neoplasms 3Multiple Myeloma 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pain 2Mesothelioma 2Lymphoma, T-Cell 2Liver Neoplasms 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × INDUSTRY × Mesothelioma, Malignant × Clear all
NCT01627795 2018-04-18

Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment

Oshadi Drug Administration

Phase 1/2 Suspended
17 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡